Abstract 1858P
Background
Prognostic factors for oncologic pts after surgery or curative systemic treatment have been described, including malnutrition, ECOG status or tumour staging. However, there is no solid evidence on which parameters predict outcomes after hospitalization of unselected cancer pts.
Methods
A review of the prospective database PLANTOLOGY of all hospitalized oncology pts between January and April 2020 at Vall d’Hebron Hospital was conducted. Clinical factors such as ECOG, comorbidities and analytical parameters were collected at admission. Mental status (depression and anxiety) and QOL were assessed through the HADS and EORTC-QLQ30 questionnaires, respectively. The identification of the optimal cut-off points was set by the maximization of the log-rank test. HLOS and overall survival (OS) since the first day of admission were calculated with the Kaplan-Meier method and univariate and multivariate Cox models were fitted to estimate hazard ratios (HR) with CI95%.
Results
Overall, 206 pts were included, median age was 65 years, 44% were active smokers, 57% had an ECOG ≤1, most frequent tumour types were lung (24%) and colorectal (15%) cancer, median Charlson comorbidity index was 9 (4 - 13) and 33% were treated under clinical trial prior to admission. Median number of treatment lines was 2 (1 - 8) with median follow-up of 2.2 months (m). The median HOLS was 8 days (CI95% 8 – 10) and median OS was 2.8 m (CI95% 2.1 – NA). Longer HOLS was observed in pts with ECOG≥2 (HR: 1.33, p=0.04) and albumin <3.3 mg/dL (HR: 1.61, p<0.001). In OS analysis, EORTC-QL30≥65, HADS≥11, LDH≥365, ECOG≥2, Stage=4 and albumin<3.3 were associated with worse OS (all p-values <0.05). In the multivariable analysis, the most parsimonious model included: HADS, stage and ECOG. HADS depression scale ≥11 was an independent factor for worse OS after adjusting for ECOG and stage (HR: 2.17; (1.08 – 4.36), p= 0.001).
Conclusions
In our cohort, QOL and depression scores measured with standardized tests were associated with OS after oncology ward admission, independently of stage and ECOG status. Factors linked to nutritional status and disease aggressiveness remain strong predictors of HOLS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d'Hebron Institute of Oncology.
Funding
Has not received any funding.
Disclosure
O. Mirallas: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Kyowa Kirin; Travel/Accommodation/Expenses: Leo Pharma. D.E. López Valbuena: Travel/Accommodation/Expenses: Kyowa Kirin; Pierre Fabre. M.A. Rezqallah Aron: Travel/Accommodation/Expenses: Kyowa Kirin. G. Villacampa Javierre: Honoraria (institution), Speaker Bureau/Expert testimony: Merck Sharp & Dohme; Advisory/Consultancy: Astrazeneca. R. Dienstmann: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Ipsen; Amgen; Servier; Sanofi; Speaker Bureau/Expert testimony, Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): Pierre fabre. J. Carles: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Research grant/Funding (institution): Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Johnson&Johnson; Travel/Accommodation/Expenses: Ipsen; Research grant/Funding (institution): AB Science; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Research grant/Funding (institution): Astellas Pharma; Pfizer; Sanofi; MSD Oncology;Speaker Bureau/Expert testimony: Asofarma; Research grant/Funding (institution): Aragon Pharmaceuticals; AVEO Pharmaceuticals; Blueprint Medicine Corporation; Boehringer Ingelheim España; Clovis Oncology; Research grant/Funding (self): Arog Pharmaceuticals; BN Inmunotherapeutics; Puma Biotechnology; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Astra Zeneca. All other authors have declared no conflicts of interest.